Tracers / [67Cu]Cu-pertuzumab-PEG6-DM1
[67Cu]Cu-pertuzumab-PEG6-DM1
Also written as [Cu-67]Cu-pertuzumab-PEG6-DM1
- Radionuclide
- Cu-67 t½ 3708 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- Antibody-drug conjugate (pertuzumab-PEG6-DM1)
- Target / mechanism
- HER2-targeting via pertuzumab (domain II) antibody-drug conjugate PMID 37095184
- Clinical application
- Breast cancer (HER2-overexpressing breast cancer) theranostics PMID 37095184
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | pertuzumab-PEG6-DM1 | 37095184 2023 Br J Cancer |
Need this precursor?We can point you to suppliers for [67Cu]Cu-pertuzumab-PEG6-DM1, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 37095184. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 37095184: 'pertuzumab-PEG6-DM1'.